Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Biogen Inc (BIIB) vs Direxion Daily Semiconductor Bull 3X Shares (SOXL) Price & Performance

Biogen IncTrade
Direxion Daily Semiconductor Bull 3X SharesTrade

Price performance (Past 24H)

Key statistics

Biogen Inc vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Biogen Inc trades at $197.24 (market cap $28.34B), while Direxion Daily Semiconductor Bull 3X Shares trades at $164.95. The key difference: Biogen Inc is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals.

BIIBSOXL
Market Cap
$28.34B
Sector
HealthLeveraged / Inverse
52-Week High
$216.63$300.77
52-Week Low
$122.68$23.99
Enterprise Value
$30.62B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Biogen Inc

Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.

The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.

Direxion Daily Semiconductor Bull 3X Shares

SOXL, a 3x leveraged semiconductor ETF, trades at $165.37, down 13.99% in 24 hours amid sector-wide volatility. Technical indicators show a bearish trend with support at $159 and resistance at $168. Recent news highlights sharp declines driven by SK Hynix's expansion and AI stock sell-offs, exposing the fund's sensitivity to leverage decay and chip sector swings.

The outlook remains high-risk due to leveraged structure and semiconductor cyclicality. Near-term pressure from oversupply concerns and hedge fund selling suggests caution, though dips may attract speculative buys. Key risks include volatility decay and broader tech sentiment shifts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Read more on BIIB

About Direxion Daily Semiconductor Bull 3X Shares

SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.

Read more on SOXL